Daiichi Sankyo unveiled an ambitious oncology-focused growth plan, publishing a new FY2026-FY2030 business plan aiming for more than 3 trillion yen (~$19.1 billion) in total revenues and more than 2.3 trillion yen (~$14.6 billion) in oncology revenue by 2030, anchored by its DXd antibody-drug conjugate (ADC) portfolio and a 200 billion yen ($1.3 billion) cost optimization initiative targeting global top-five oncology rank by 2035. CSL cut FY26 revenue guidance to approximately $15.2 billion and will recognize about $5 billion in non-cash impairments across FY26 and FY27, including a major Vifor kidney business writedown; shares fell as much as ~22%. The FDA approved LANGLARA (insulin glargine-aldy) from Lannett, Lanexa Biologics, and Sunshine Lake Pharma on April 29, 2026 as an interchangeable biosimilar to Sanofi’s Lantus, and on April 14 issued draft guidance on safety testing for gene-editing therapies. GSK entered an exclusive 5.5-year collaboration with Sino Biopharmaceutical’s CTTQ subsidiary to commercialize bepirovirsen in mainland China. NICE cleared Italfarmaco’s Duvyzat (givinostat) for NHS England use in ambulant Duchenne muscular dystrophy patients aged 6 and over.
What to Watch
- Daiichi’s ADC expansion — With $15B in oncology sales targeted by 2030 and a $1.3B cost optimization program, watch whether the company can execute pipeline milestones and fend off biosimilar/competitive pressures in its core franchises.
- CSL’s restructuring response — The $5B impairment and revenue cut signal deep integration challenges post-Vifor; portfolio rationalization and potential divestitures may follow to restore investor confidence.
- Biosimilar insulin uptake — Lannett’s interchangeable insulin glargine approval tests whether regulatory parity translates to market penetration against entrenched brands and PBM formulary dynamics.
- China partnerships as strategic imperative — GSK’s exclusive bepirovirsen collaboration with Sino Biopharmaceutical’s CTTQ subsidiary underscores the trend of Western biopharmas leveraging local partners for China market access and reimbursement navigation.
